Download Safinamide - Analysis and Estimates from 2012 to 2020 Brochure

Brochure
More information from http://www.researchandmarkets.com/reports/1934538/
Safinamide - Analysis and Estimates from 2012 to 2020
Description:
Safinamide – Analysis and Estimates from 2012 to 2020
Summary
GlobalData’s pharmaceuticals report, “Safinamide – Analysis and Estimates from 2012 to 2020” provides
Safinamide(sales estimates for US and EU5 . In addition, it covers detailed clinical assessment of the drug,
factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast
period (2012-2020). The report also includes information on Parkinson's Disease market. This report is built
using data and information sourced from GlobalData’s proprietary databases, primary and secondary
research using Company’s corporate website, SEC filings, investor presentations and featured press
releases, both from company and industry-specific third party sources, put together with in-house analysis,
by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the Japan (seven major markets)
- Analysis and review of Safinamide including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Safinamide including efficacy, safety, pricing, competition and other details which
influence its sales potential
- Detailed sales forecast for 2012-2020 for Safinamide in the US and EU5
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales
potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Contents:
1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Parkinson’s Disease
2.2 Symptoms of Parkinson’s Disease
2.3 Diagnosis of Parkinson’s Disease
2.4 Parkinson’s Disease Treatment Strategies
2.5 Parkinson’s Disease Market
2.6 Epidemiology
2.7 Parkinson’s Disease by Age and Gender
2.8 Etiology
2.9 GlobalData Report Guidance
3 Parkinson’s Disease: Market Characterization
3.1 Parkinson’s Disease Market
3.2 Parkinson’s Disease Market Forecasts and CAGR
3.3 Factors Affecting Parkinson’s Disease Market
3.3.1 High Prevalence: Parkinson’s Disease is the Second Most Frequent Neurodegenerative Disorder
3.3.2 Increase in Old Age Population
3.3.3 Patent Expiry of Prominent Drugs
4 Stages of Parkinson’s Disease and Comparison of Treatments
4.1 The Hoehn and Yahr Scale
4.2 Modified Hoehn and Yahr Scale
4.3 The UPDRS
5 Staging of Parkinson’s Disease
5.1 Distribution of Parkinson’s Disease Patients by Age Groups
5.2 Distribution of Patients by Stages
6 Safinamide
6.1 Introduction
6.2 Mechanism of Action
6.3 Clinical Studies
6.3.1 SETTLE Study with Safinamide as an Add On to a Dopamine Agonist in Patients with Early Parkinson's
Disease
6.3.2 Long Term Efficacy and Safety of Safinamide as an Add On to Levodopa in Patients with Advanced
Parkinson’s Disease
6.4 Factors Affecting Sales of Safinamide
6.4.1 Add on to DAs
6.4.2 Potential Benefits
6.4.3 Motor and Non Motor Systems
6.4.4 No statistically Significant Improvement in Primary End Point
6.4.5 Patent Expiry of Dopamine Agonists
6.5 Drug Evaluation
6.5.1 Drug Risk Benefit Score
6.5.2 Intensity of Competition
6.6 Sales Forecasts
6.6.1 Target Patient Pool for Safinamide
6.6.2 Dosing
6.6.3 Market Penetration
6.6.4 Annual Cost of Therapy
6.6.5 Sales Projections of Safinamide
7 Parkinson Disease Market: Appendix
7.1 Market Definitions
7.2 List of Abberiviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Number of Patients Approved to take the Drug
7.3.5 Net Penetration of Drug
7.3.6 Net Annual Dosing
7.3.7 Annual Cost of Therapy
7.3.8 Primary Research
7.3.9 Expert Panels
7.4 Drug Sales Estimates Model
7.5 Contact Us
7.6 Disclaimer
7.7 Sources
1.1 List of Tables
Table 1: Clinical Motor and Nonmotor Features of Parkinson’s Disease
Table 2: Hoehn and Yahr Stages of Parkinson’s Disease
Table 3: Hoehn and Yahr Stages of Parkinson’s Disease
Table 4: Four Items, Part 1 of UPDRS
Table 5: Thirteen Items, Part 2 of UPDRS
Table 6: Fourteen Items, Part 3 of UPDRS
Table 7: Fourteen Items, Part 3 of UPDRS
Table 8: Distribution of Parkinson’s Patients According to Hoehn and Yahr Classification
Table 9: UPDRS III Scores in The Intention To Treat Cohort and in Patients Taking One DA Agonist
Table 10: Study Results for Safinamide as Add-On to Levodopa In Patients with Advanced Parkinson’s
Disease
Table 11:Drug Risk Benefit Score (DRB)-Safinamide
Table 12: Efficacy Comparison of Safinamide with other Competitors
Table 13: Annual Cost of Safinamide for Parkinson’s Disease, 2011
Table 14: Safinamide, Parkinson’s Disease, Global, Sales Forecasts ($m), 2012-2020
Table 15: Safinamide, Parkinson’s Disease, The US, Sales Forecasts ($m), 2012–2020
Table 16: Safinamide, Parkinson’s Disease, The UK, Sales Forecasts ($m), 2012–2020
Table 17: Safinamide, Parkinson’s Disease, France, Sales Forecasts ($m), 2012–2020
Table 18: Safinamide, Parkinson’s Disease, Germany, Sales Forecasts ($m), 2012–2020
Table 19: Safinamide, Parkinson’s Disease, Italy, Sales Forecasts ($m), 2012–2020
Table 20: Safinamide, Parkinson’s Disease, Spain, Sales Forecasts ($m), 2012–2020
1.2 List of Figures
Figure 1: Current Pharmacologic Therapies for Parkinson’s disease and Their Potential Sites of Action in the
CNS
Figure 2: The Age-Specific Prevalence Rates of Parkinson’s Disease in the Elderly Among Five European
Countries, 2003
Figure 3: Parkinson’s Disease, Global, Market Size Estimates ($bn), 2010–2020
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050
Figure 5: Points Distribution of UPDRS
Figure 6: Distribution of Parkinson’s Disease Patients by Hoehn & Yahr Classification
Figure 7: Drug Model Diagram of Safinamide in the US and EU
Figure 8: Safinamide, Parkinson’s Disease, Global, Sales Forecasts ($m), 2012-2020
Figure 9: Safinamide, Parkinson’s Disease, The US, Sales Forecasts ($m), 2012–2020
Figure 10: Safinamide, Parkinson’s Disease, The UK, Sales Forecasts ($m), 2012–2020
Figure 11: Safinamide, Parkinson’s Disease, France, Sales Forecasts ($m), 2012–2020
Figure 12: Safinamide, Parkinson’s Disease, Germany, Sales Forecasts ($m), 2012–2020
Figure 13: Safinamide, Parkinson’s Disease, Italy, Sales Forecasts ($m), 2012–2020
Figure 14: Safinamide, Parkinson’s Disease, Spain, Sales Forecasts ($m), 2012–2020
Figure 15: Safinamide, Parkinson’s Disease, Global, Sales Distribution by Country (%), 2020
Figure 16: Drug Model Diagram
Figure 17: Patients Approved for the Drug
Ordering:
Order Online - http://www.researchandmarkets.com/reports/1934538/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Safinamide - Analysis and Estimates from 2012 to 2020
Web Address:
http://www.researchandmarkets.com/reports/1934538/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Site License:
USD 4000
Electronic (PDF) Single User:
USD 2000
Electronic (PDF) Enterprisewide:
USD 6000
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World